Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Saved in:
Bibliographic Details
Title: Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Authors: Yhim, Ho-Young1, Lee, Na-Ri1,2, Song, Eun-Kee1,2, Yim, Chang-Yeol1,2, Jeon, So Yeon1, Shin, Seunghwan3, Kim, Jeong-A3, Kim, Hee Sun4, Cho, Eun Hae5, Kwak, Jae-Yong1,2 jykwak@jbnu.ac.kr
Source: Leukemia Research. Jun2012, Vol. 36 Issue 6, p689-693. 5p.
Database: Academic Search Ultimate
Description
ISSN:01452126
DOI:10.1016/j.leukres.2012.02.011